Read by QxMD icon Read

Gynecologic Oncology

Julia R Salinaro, Allison M Puechl, Laura J Havrilesky, Brittany A Davidson
OBJECTIVE: To investigate trends in the representation of women as first, last, or co-authors in Gynecologic Oncology (GO) publications over the past 15 years. To compare rates of female authorship in GO versus general Obstetrics and Gynecology (Ob/Gyn) and with the gender distribution of membership in the Society of Gynecologic Oncology (SGO). METHODS: Gender was determined for first and last authors of GO publications from three major journals for 2000, 2005, 2010, and 2015...
October 9, 2018: Gynecologic Oncology
C Bethan Powell, Amy Alabaster, Mary Anne Armstrong, Nicole Stoller, Tina Raine-Bennett
OBJECTIVE: Estimate the prevalence of cardiovascular disease risk factors and endpoints in women with BRCA mutations. METHODS: Women, age 40 and older, with BRCA mutations identified in Kaiser Permanente Northern California completed a questionnaire and underwent a lipid and fasting glucose panel. Bivariable analysis of clinical and demographic factors was performed. The Atherosclerotic Cardiovascular Disease (ASCVD) calculator was used to predict 10-year risk of a cardiovascular event...
October 9, 2018: Gynecologic Oncology
Hyun-Soo Kim, Ji-Ye Kim, Yong Jae Lee, So Hee Kim, Jung-Yun Lee, Eun Ji Nam, Sunghoon Kim, Sang Wun Kim, Young Tae Kim
OBJECTIVE: To investigate the prognostic value of the expressions of programmed cell death ligand 1 (PD-L1) and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy (NAC) for advanced high-grade serous ovarian cancer (HGSOC). METHODS: We collected pre- and post-NAC tumor samples from patients with advanced HGSOC between 2006 and 2017. Post-NAC tumor tissue samples were available for immunostaining from 131 patients. The expressions of PD-L1 and immune checkpoint markers were assessed by immunohistochemical staining and the status of tumor-infiltrating lymphocytes (TILs) was also evaluated...
October 9, 2018: Gynecologic Oncology
R Wendel Naumann, Jacob C Morris, David L Tait, Robert V Higgins, Erin K Crane, Lane K Drury, Lisa Amacker-North, Megan Templin, Jubilee Brown
OBJECTIVES: To compare the outcomes after intraperitoneal (IP) chemotherapy in patients with and without pathogenic BRCA mutations. METHODS: Patients with high grade ovarian cancer who were treated with adjuvant IP chemotherapy in the initial setting between 2005 and 2016 were identified. Outcomes were compared between patients with pathogenic mutations in BRCA (BRCA+) and those who tested negative or were unknown (BRCA-). RESULTS: A total of 100 eligible patients were identified...
October 8, 2018: Gynecologic Oncology
Bradley J Monk, James T Kauderer, Katherine M Moxley, Albert J Bonebrake, Summer B Dewdney, Angeles Alvarez Secord, Frederick R Ueland, Carolyn M Johnston, Carol Aghajanian
OBJECTIVE: Preclinical data suggest elesclomol increases oxidative stress and enhances sensitivity to cytotoxic agents. The objective of this prospective multicenter phase 2 trial was to estimate the activity of IV elesclomol plus weekly paclitaxel in patients with platinum-resistant recurrent ovarian, tubal or peritoneal cancer through the frequency of objective tumor responses (ORR). METHODS: Patients with measurable disease, acceptable organ function, performance status ≤ 2, and one prior platinum containing regimen were eligible...
October 8, 2018: Gynecologic Oncology
David K Gaffney, Mia Hashibe, Deanna Kepka, Kathryn A Maurer, Theresa L Werner
One woman dies from cervix cancer every 2 min, adding up to over 270,000 deaths globally per year. This cancer affects a young population, and hence, the loss of life is staggering. There are many aspects of prevention, screening, and care that are suboptimal. A great deal is known about HPV induced carcinogenesis, yet clinical outcomes have been stagnant over decades. There has been no improvement in cervix cancer survival in the US since the mid-1970s [1]. With increased knowledge of the disease and greater worldwide resources including prevention, screening, and improved therapeutics, there is significant promise for fewer women to die from this virally induced cancer...
October 6, 2018: Gynecologic Oncology
Anil Belur Nagaraj, Peronne Joseph, Olga Kovalenko, QuanQiu Wang, Rong Xu, Analisa DiFeo
OBJECTIVE: To evaluate the utility of amiodarone and its derivative dronedarone as novel drug repositioning candidates in EOC and to determine the potential pathways targeted by these drugs. METHODS: Drug-predict bioinformatics platform was used to assess the utility of amiodarone as a novel drug-repurposing candidate in EOC. EOC cells were treated with amiodarone and dronedarone. Cell death was assessed by Annexin V staining. Cell viability and cell survival were assessed by MTT and clonogenics assays respectively...
October 6, 2018: Gynecologic Oncology
Jinglu Wang, Dylan C Dean, Francis J Hornicek, Huirong Shi, Zhenfeng Duan
Despite the surgical and chemotherapeutic advances over the past few decades, ovarian cancer remains the leading cause of gynecological cancer-related mortality. The absence of biomarkers in early detection and the development of drug resistance are principal causes of treatment failure in ovarian cancer. Recent progress in RNA sequencing (RNA-Seq) with Next Generation Sequencing technology has expanded the understanding of the molecular pathogenesis of ovarian cancer. As compared to previous hybridization-based microarray and Sanger sequence-based methods, RNA-Seq provides multiple layers of resolutions and transcriptome complexity, with less background noise and a broader dynamic range of RNA expression...
October 5, 2018: Gynecologic Oncology
Pauline McGee, David Alex Munnoch
OBJECTIVE: To evaluate outcomes in patients with gynaecological cancer related lymphoedema treated with liposuction. METHODS: A prospective analysis of 21 patients who underwent liposuction followed by compression therapy for chronic unilateral lower limb lymphoedema with up to 8 years follow up was performed. RESULTS: Duration of lymphoedema prior to liposuction ranged from 4 to 28 years (mean 15.2 years). The mean age at time of liposuction was 52 years (range 37-67)...
October 4, 2018: Gynecologic Oncology
Joanne K Rash, Karen D Lyle, Arati Jairam-Thodla, Yevgeniya Ioffe
No abstract text is available yet for this article.
October 4, 2018: Gynecologic Oncology
Alessia Aloisi, João Miguel Casanova, Jill H Tseng, Kristina A Seader, Nancy Thi Nguyen, Kaled M Alektiar, Vicky Makker, Sarah Chiang, Robert A Soslow, Mario M Leitao, Nadeem R Abu-Rustum
OBJECTIVE: To assess the rates and distribution of first recurrence in patients with FIGO stage IIIC1 endometrial cancer (EC) who did not undergo paraaortic dissection at surgical staging. METHODS: We retrospectively selected all (n = 207) stage IIIC1 patients treated at a single institution from 5/1993-1/2017. Sites of first recurrence were identified, disease-free (DFS) and overall survival (OS) calculated, multivariate logistic regression performed to identify factors associated with recurrence...
October 1, 2018: Gynecologic Oncology
Adam C ElNaggar, Erinn M Hade, David M O'Malley, Margaret I Liang, Larry J Copeland, Jeffrey M Fowler, Ritu Salani, Floor J Backes, David E Cohn
OBJECTIVE: To assess compliance with, and outcomes related to, the Society of Gynecologic Oncology quality measure in ovarian cancer to administer chemotherapy within 42 days of cytoreductive surgery in patients with epithelial ovarian/fallopian tube/peritoneal cancer. METHODS: Institutional ovarian cancer database was evaluated for compliance with the quality measure to administer chemotherapy within 42 days of cytoreductive surgery. The influence of chemotherapy timing on the risk of death was evaluated, and factors related to the timing of chemotherapy after surgery was assessed...
September 30, 2018: Gynecologic Oncology
Sara Nasser, Konstantinos Lathouras, Katherine Nixon, Jeremy Campbell, Gary Stocks, Long Jiao, Christina Fotopoulou
OBJECTIVE: Evaluate postoperative hepatic-function in patients with advanced ovarian cancer (OC) who underwent extensive right upper-quadrant (RUQ) cytoreduction in primary, relapsed or interval settings. METHODS: We retrospectively reviewed all patients with OC who underwent liver resection, mobilization and/or diaphragmatic-stripping between 01/2013 and 12/2016. Postoperative liver enzyme function (LFTs), assessed by alanine transaminase (ALT), alkaline phosphatase (ALP) and bilirubin (Bil), was correlated with postoperative complications...
September 29, 2018: Gynecologic Oncology
Michelle van der Linden, Edith van Esch, Johan Bulten, Enno Dreef, Leon Massuger, Sophieke van der Steen, Tjalling Bosse, Joanne de Hullu, Mariëtte van Poelgeest
BACKGROUND: Non-invasive vulvar Paget disease (VPD) is a rare skin disorder mainly affecting elderly women. Recently, the immune modulator imiquimod was reported as an effective treatment option. Knowledge about the immune microenvironment of VPD is lacking. METHODS: This study investigates the basic characteristics of the immune infiltrate in VPD (n = 10); moreover the influence of imiquimod was studied (n = 6). Immunohistochemistry for CD4, CD8, CD14, CD20, CD56 and FoxP3 was performed...
September 28, 2018: Gynecologic Oncology
Li Zhang, Xiao-Qian Xu, Shang-Ying Hu, Feng Chen, Xun Zhang, Qin-Jing Pan, Wen-Hua Zhang, Rui-Mei Feng, Li Dong, Qian Zhang, Jun-Fei Ma, Catherine Sauvaget, Fang-Hui Zhao, You-Lin Qiao, Rengaswamy Sankaranarayanan
OBJECTIVE: Self-collected HPV testing could substantially reduce disparities in cervical cancer screening, with slightly lower sensitivity compared to physician-collected specimens cross-sectionally. We aimed to evaluate the comprehensive long-term performance of self-collected HPV testing prospectively. METHODS: In 1999, 1997 women were screened by HPV testing on self-collected and physician-collected samples, cytology and visual inspection with acetic acid (VIA) and followed up in 2005, 2010 and 2014, respectively...
September 27, 2018: Gynecologic Oncology
Ayumu Matsuoka, Shinichi Tate, Kyoko Nishikimi, Makio Shozu
No abstract text is available yet for this article.
September 27, 2018: Gynecologic Oncology
Rahul Shenolikar, Emily Durden, Nicole Meyer, Gregory Lenhart, Kathleen Moore
OBJECTIVE: Real-world data on patients with cancer developing secondary malignancies such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are lacking. This study assessed the incidence and impact of select DNA-damaging therapy exposure on risk of secondary MDS and AML in patients with ovarian cancer (OC) or breast cancer (BC). METHODS: Adults with a first observed OC or BC diagnosis (index date) between 1/1/2000 and 6/30/2014 were identified from MarketScan® Commercial and Medicare databases...
September 26, 2018: Gynecologic Oncology
Giorgia Mangili, Raffaella Cioffi, Saverio Danese, Luigi Frigerio, Gabriella Ferrandina, Gennaro Cormio, Emanuela Rabaiotti, Giovanna Scarfone, Angiolo Gadducci, Alice Bergamini, Carmela Pisano, Massimo Candiani
OBJECTIVE: To compare clinical outcomes of patients diagnosed with low-risk gestational trophoblastic neoplasia (GTN) receiving intramuscular methotrexate 50 mg total dose/day versus 1 mg/kg/day in a 8-day methotrexate/folinic acid (MTX/FA) regimen. METHODS: This retrospective, multicenter study included 176 patients: 99 (56%) receiving methotrexate 50 mg total dose/day on days 1, 3, 5, 7 alternated with FA 7,5 mg on days 2, 4, 6, 8, every 14 days (group A); and 77 patients (44%), receiving methotrexate 1 mg/kg/day on days 1, 3, 5, 7 alternated with FA 7,5 mg on days 2, 4, 6, 8, every 14 days (group B)...
September 26, 2018: Gynecologic Oncology
Weiping Wang, Fuquan Zhang, Ke Hu, Xiaorong Hou
OBJECTIVE: Image guidance should be used for patients with cervical cancer treated with definitive intensity-modulated radiation therapy (IMRT). In this study, we provided a pattern of image guidance and verified it in a large population. METHODS: We retrospectively analyzed patients with stages IB1-IVA cervical cancer treated with IMRT combined with high-dose brachytherapy and concurrent chemotherapy in our institute from January 2005 to December 2015. A dose of 50...
September 25, 2018: Gynecologic Oncology
Vivian M Spaans, Daniëlla A Scheunhage, Bianca Barzaghi, Cor D de Kroon, Gert J Fleuren, Tjalling Bosse, Ekaterina S Jordanova
OBJECTIVE: Recently, the pattern of invasion in usual-type human papillomavirus-associated endocervical adenocarcinoma (AC) was put forward as a novel variable to select patients with favourable prognosis. Based on destructiveness of stromal invasion, three patterns were proposed: A - no destructive stromal invasion, B - focal destructive stromal invasion, and C - diffuse destructive stromal invasion. We aimed to independently validate the clinical significance of this classification-system in 82 AC patients, and explored associations between invasion pattern and somatic mutations...
September 24, 2018: Gynecologic Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"